Literature DB >> 24787958

MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3.

Ling Wang1, Liyuan Qian1, Xiaorong Li1, Jin Yan2.   

Abstract

MicroRNA (miR)‑195 has been reported to be a tumor suppressor. Downregulation of miR‑195 has been shown to correlate with lymph node metastasis and poor prognosis in colorectal cancer. However, the specific regulatory role of miR‑195 in colorectal cancer cells is yet to be elucidated. In the present study, miR‑195 expression was significantly reduced in colorectal cancer tissues. Furthermore, CARMA3 was identified as a novel target of miR‑195, which was observed to be upregulated in colorectal cancer. In addition, downregulation of miR‑195 increased CARMA3 protein expression, whereas miR‑195 upregulation suppressed CARMA3 protein expression in SW480 and HT29 colorectal cancer cells. Moreover, overexpression of miR‑195 downregulated cell proliferation, colony‑formation and invasion in SW480 and HT29 cells, which was reversed upon CARMA3 overexpression. In conclusion, the findings of the present study suggest that miR‑195 has a suppressive role in colorectal cancer cells through directly targeting CARMA3. Therefore, CARMA3 may be a potential target for the treatment of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24787958     DOI: 10.3892/mmr.2014.2178

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  24 in total

1.  microRNA-195-Cdc42 axis acts as a prognostic factor of esophageal squamous cell carcinoma.

Authors:  Niuniu Sun; Lin Ye; Tingmin Chang; Xiaojing Li; Xiumin Li
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 2.  The role of miRNAs in the pheochromocytomas.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen
Journal:  Tumour Biol       Date:  2015-10-13

3.  MicroRNA-195 suppresses colorectal cancer cells proliferation via targeting FGF2 and regulating Wnt/β-catenin pathway.

Authors:  Xianxiang Zhang; Ji Xu; Tao Jiang; Guangwei Liu; Dongsheng Wang; Yun Lu
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

4.  MiR-375 targets KLF4 and impacts the proliferation of colorectal carcinoma.

Authors:  Qiqi Mao; Tao Quan; Bin Luo; Xuefeng Guo; Lei Liu; Qinghui Zheng
Journal:  Tumour Biol       Date:  2015-07-30

5.  MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA.

Authors:  Min Wang; Junjie Zhang; Linlong Tong; Xiaofei Ma; Xinguang Qiu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

6.  miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells.

Authors:  Chunhui Liu; Han Guan; Yiduo Wang; Ming Chen; Bin Xu; Lei Zhang; Kai Lu; Tao Tao; Xiaowen Zhang; Yeqing Huang
Journal:  PLoS One       Date:  2015-12-09       Impact factor: 3.240

7.  miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis.

Authors:  Maria Ines Almeida; Andreia Machado Silva; Daniel Marques Vasconcelos; Catarina Rodrigues Almeida; Hugo Caires; Marta Teixeira Pinto; George Adrian Calin; Susana Gomes Santos; Mário Adolfo Barbosa
Journal:  Oncotarget       Date:  2016-01-05

8.  miR-195 is a key regulator of Raf1 in thyroid cancer.

Authors:  Fangzheng Wang; Chuner Jiang; Quanquan Sun; Fenqin Yan; Lei Wang; Zhenfu Fu; Tongxin Liu; Fujun Hu
Journal:  Onco Targets Ther       Date:  2015-10-20       Impact factor: 4.147

9.  Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients.

Authors:  I-Ping Yang; Hsiang-Lin Tsai; Zhi-Feng Miao; Ching-Wen Huang; Chao-Hung Kuo; Jeng-Yih Wu; Wen-Ming Wang; Suh-Hang Hank Juo; Jaw-Yuan Wang
Journal:  J Transl Med       Date:  2016-04-29       Impact factor: 5.531

10.  Development and validation of a novel miRNA classifier as a prognostic signature for stage II/III colorectal cancer.

Authors:  Junlan Feng; Qing Wei; Muqing Yang; Xiaodong Wang; Bin Liu; Jiyu Li
Journal:  Ann Transl Med       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.